The global churg Strauss syndrome market is expected to grow during the forecast period (2018 to 2023) at a CAGR of ~ 4.1 %.
Churg Strauss syndrome is a disorder that causes inflammation in blood vessels. This restricts the blood flow to vital organs and tissues. Sometimes it leads to permanent damage of tissues. This condition is also known as eosinophilic granulomatosis with polyangiitis. Asthma is the most common sign of churg Strauss syndrome. It also affects nose, sinuses, lung, heart, and nerves. There are no medications on this and while it is rare some people got this disease because of asthma medication called Montelukast. As due to change in environmental conditions lots of people are suffering from allergic and immune disorders. Hence this leads to an increase in the growth of this market.
Factors such as growing occurrences of churg Strauss syndrome and other allergic reactions and asthma, rising geriatric population, and growing incidences of churg Strauss syndrome in children are expected to drive the growth of the market during the assessment period.
On the other hand, the unfavorable reimbursement scenario in many developing countries and lack of awareness regarding autoimmune disorder in people can hinder the growth of the market during the forecast period.
Segmentation
The global churg Strauss syndrome market is segmented on basis of diagnosis, treatment, end users. Based on diagnosis the churg Strauss syndrome market is further segmented into blood test, imaging, biopsy, chest x-ray, CT scan. On basis of treatment, the syndrome is further segmented into biologics, immunoglobulin, corticosteroid, immunosuppressive drugs and others. Immunoglobulin is further sub-segmented into vaccines, steroids, and others. Based on end users the churg Strauss syndrome is further segmented into hospitals, clinics, laboratory, therapeutics aspects, and others.
Key players
Some of the key players in the global churg Strauss syndrome market are Slivergate, Heron Therapeutics, Inc., IRX Therapeutics, Inc., Brabourne Enterprises Ltd, Rupus Research Alliance, Tianjin Tianyao Pharmaceuticals Co., Ltd, and Grifols, S.A.
Global Churg Strauss Syndrome Market, by Diagnosis
Global Churg Strauss Syndrome Market, by treatment
Global Churg Strauss Syndrome Market, by End-User